Four years ago, Eli Lilly was a solid, slow-moving pharmaceutical company with a net margin hovering around 20% and a stock that rewarded patience rather than excitement. Then tirzepatide arrived, first as Mounjaro for type 2 diabetes in May 2022, then as Zepbound for weight loss in November 2023, and the company’s financial profile changed shape entirely. Today the stock trades at $1,273, up nearly 57% in twelve months, and the price carries an assumption about future profitability that deserves a hard look against what the filings actually show.
The tension is this: the math in the filings is genuinely extraordinary, and the mood, meaning what the market is currently paying per dollar of earnings, is not obviously crazy. But those two things are only compatible if a very specific margin story keeps running. That story is the one worth auditing.
In one breath
Lilly’s filed 2025 results show a net margin of 31.7%, the highest in at least five years and a genuine structural improvement driven by GLP-1 drug volume. The stock’s current price-to-sales ratio sits above its own decade median, meaning the market is paying a premium over Lilly’s historical average just to own each dollar of revenue. Those two readings are only consistent if margins keep expanding toward the company’s own guided performance margin of 49% to 50.5% for 2026. The open question is whether a business facing pricing headwinds, a debt load larger than its entire annual revenue just two years ago, and a rapidly crowding competitive field can actually close that gap.
What the filings show
Start with the margin climb, because it is the whole story. In fiscal 2023, Lilly’s net margin was 15.4%, compressed by the early costs of scaling a new drug franchise. By fiscal 2025, it had more than doubled to 31.7%, as Mounjaro and Zepbound moved from launch phase to cash-generating scale. That is not a rounding error. It is a business that learned to sell the same molecule in higher volumes without proportionally higher costs, the pharmaceutical equivalent of a factory running at full shift after years of half-capacity.
The Q2 2026 filing shows the trajectory continuing. Mounjaro worldwide revenue hit $9.9 billion in the quarter alone, nearly doubling year over year, and Zepbound U.S. revenue reached $4.9 billion, up nearly half again on the same period last year. Together, those two drugs generated roughly two dollars of every three that Lilly collected in the quarter. The company then revised its full-year 2026 revenue guidance to $85 billion to $87 billion. For context, the entire company earned $45 billion in revenue in all of fiscal 2024. Lilly is now guiding to nearly double that in a single year.
The operating margin picture is where the price assumption lives. Our data show Lilly’s trailing twelve-month operating margin as of September 2026 at 43%, and the company’s own full-year 2026 guidance targets a non-GAAP performance margin of 49% to 50.5%. That is a meaningful step up from even the strong 2025 result, and it is the number the stock’s current price-to-sales multiple of 18.5 needs to believe in. The decade median for that multiple is 15.8, meaning the market is paying about 17% more per dollar of revenue than it historically has. That premium is only justified if the margin on each of those revenue dollars keeps rising.
What the price is betting on
A price-to-earnings ratio, the multiple, is simply the price tag per dollar of annual profit. Lilly’s current P/E of 58.5 sits just below its own decade median of 62.2, which sounds reassuring until you remember that the decade median was built during years when earnings were far smaller and the growth story was still unproven. The market is essentially saying: we believe the 2025 margin expansion was structural, not temporary, and we believe it continues.
Goldman Sachs, as reported by The Street on October 23, 2026, published a 12-month valuation level of $1,413 based on revenue projections above even Lilly’s own guidance ceiling, one data point in a range of analyst views that readers can weigh against the filing-based analysis above. The consensus 2026 EPS estimate sits somewhat below Lilly’s own non-GAAP guidance midpoint, partly because GAAP results absorb acquisition charges that non-GAAP figures exclude. Analyst projections for 2027 earnings are meaningfully higher still. If those figures materialize and the stock holds its current price, the forward multiple would compress toward more historically ordinary levels, the arithmetic behind the argument that today’s elevated price-to-sales ratio is a leading indicator of earnings growth rather than overvaluation.
The bear case is quieter but worth hearing. Analysts cited by Traders Union flag mid-teens pricing headwinds across Lilly’s global portfolio for 2026, meaning the company must sell meaningfully more volume just to hold revenue flat against price erosion. Novo Nordisk’s oral Wegovy, launched in January 2026, still commands roughly three-quarters of new prescriptions over Lilly’s own oral GLP-1, Foundayo, which the FDA approved for obesity in April 2026 and which posted a promising but still modest start in Q2 2026. Viking Therapeutics and Structure Therapeutics are advancing their own candidates. The GLP-1 market is not a monopoly; it is a race.
The debt and the pipeline
Lilly is not a company sitting still. The Q2 2026 10-Q shows total debt of $54.9 billion, a figure worth anchoring: that is more than the entire company earned in revenue in fiscal 2024. Free cash flow over the trailing twelve months through June 2026 reached $18.2 billion, so the debt is serviceable, but it is not trivial. The company has spent heavily on acquisitions across more than a dozen deals by September 2026, buying Orna Therapeutics, Ajax Therapeutics, and Kelonia Therapeutics among others, and broke ground on a major new manufacturing facility in Houston as part of a broader $50 billion U.S. expansion. Research and development spending rose sharply in the first quarter of 2026 alone.
The pipeline bets are large and the timelines are real. Retatrutide, a next-generation weight-loss drug that showed substantial body weight reduction in Phase 3 trials, is on track for regulatory submission in early 2027. Olomorasib data presented at ESMO 2026 on October 25 showed a strong overall response rate in a difficult-to-treat lung cancer population. Kisunla, the Alzheimer’s drug, showed sustained amyloid clearance in the vast majority of patients at three years. These are not hypothetical; they are filed and dated results. Whether they translate into revenue at the scale the stock price implies is the question the filings cannot yet answer.
The documented record shows margin expansion is real, the growth trajectory through 2026 is extraordinary by any historical comparison, and the current price embeds the assumption that both continue without meaningful interruption from competition, pricing pressure, or execution risk on a manufacturing build-out larger than most companies’ entire balance sheets.
Reading the numbers
- Net margin, 31.7% in FY2025 (10-K filed February 2026). This is what Lilly keeps from each dollar of sales after all costs. In 2023 that figure was 15.4 cents per dollar; by 2025 it was 31.7 cents. A bakery that doubled its profit per loaf without raising prices would be doing something structurally different, and Lilly is: high-volume drug manufacturing spreads fixed costs across more units as demand grows.
- Price-to-sales ratio, 18.5 vs. decade median of 15.8 (our data). This is the price tag per dollar of annual revenue. Lilly’s current ratio is about 17% above its own historical average. A household paying 17% above the usual asking price for a home is betting the neighborhood keeps improving. The bet here is that rising margins make each revenue dollar worth more than it historically has been.
- 2026 revenue guidance, $85 billion to $87 billion (Q2 2026 10-Q filed August 5, 2026). This is the range Lilly’s own management believes the business will generate this calendar year. For scale: the entire U.S. pharmaceutical industry generated roughly this much revenue in a single year just a decade ago. If guidance is met, Lilly will have nearly doubled its revenue in two years.
- Total debt, $54.9 billion as of June 2026 (Q2 2026 10-Q). Think of a household earning $18,000 a year in free cash flow carrying a $55,000 credit card balance. The math works as long as the income keeps coming, but a bad year changes the calculation quickly. Lilly’s free cash flow covers the debt in roughly three years at current rates, which is manageable but leaves little room for a revenue stumble.
- Non-GAAP performance margin guidance, 49% to 50.5% for full-year 2026. This is the operating profit margin Lilly’s management is targeting, meaning nearly half of every revenue dollar would become operating profit. That would be among the highest sustained margins of any large pharmaceutical company. It is the number the current stock price most directly depends on.
Sources
- Eli Lilly 10-Q, quarter ended June 30, 2026
- Eli Lilly 10-Q, quarter ended March 31, 2026
- Eli Lilly 10-K, fiscal year ended December 31, 2025
- Eli Lilly 10-K, fiscal year ended December 31, 2024
- Eli Lilly 10-K, fiscal year ended December 31, 2023
- Eli Lilly Q2 2026 earnings release
- MarketBeat, FY2027 EPS estimates, October 23, 2026
- The Street, Goldman Sachs analyst valuation level, October 2026
- PR Newswire, olomorasib ESMO 2026 data, October 25, 2026
- Lilly investor relations, Mounjaro cardiovascular approval, August 28, 2026
- Traders Union, GLP-1 growth outlook
- Exploding Topics, GLP-1 market size projections
